Abstract:We report the clinical and immune features of 7 individuals from the same kindred with a novel genetic variant in RAC2 (c.62T > G, p.I21S). We provide evidence that this is a dominant activating (DA) variant causing notable morphological and functional abnormalities similar to other reported DA mutations. This novel variant expands the phenotypic spectrum of RAC2 DA lesions, emphasising the need to tailor clinical management according to patients' disease phenotype and severity. Objectives Dominant‐activating (DA) lesions in RAC2 have been reported in 18 individuals to date. Some have required haematopoietic stem cell transplantation (HSCT) for their (severe) combined immunodeficiency syndrome phenotype. We aimed to investigate clinical and cellular features of a kindred harbouring a novel variant in RAC2 p.Ile21Ser (I21S) to better understand DA lesions' phenotypic spectrum. Methods Clinical and immunological information was collated for seven living individuals from the same kindred with RAC2 p.I21S. We evaluated neutrophil morphology, RAC2 protein expression and superoxide production using freshly isolated neutrophils stimulated with phorbol‐12‐myristate‐13‐acetate (PMA) and N‐formyl‐MetLeuPhe (fMLP). Results Patient 1 (P1, aged 11, male) has a history of bacterial suppurative otitis media, viral and bacterial cutaneous infections. P1's siblings (P2, P3), mother (P4), maternal aunt (P5) and uncle (P6) have similar infection histories. P1's maternal cousin (P7) presented with Burkitt's lymphoma at age 9. All affected individuals are alive and none has required HSCT to date. They have chronic lymphopenia affecting the CD4+T and B‐cell compartments. P1–3 have isolated reduction in IgM levels whereas the adults universally have normal immunoglobulins. Specific antibody responses are preserved. Affected individuals have neutrophil vacuolation, and their neutrophils have enhanced superoxide production compared to healthy controls. Conclusion RAC2 p.I21S is an activating variant causing notable morphological and functional abnormalities similar to other reported DA mutations. This novel variant expands the broad clinical phenotypic spectrum of RAC2 DA lesions, emphasising the need to tailor clinical management according to patients' disease phenotype and severity.

A Novel RAC2 Mutation Causing Combined Immunodeficiency

Combined Immunodeficiency Caused by a Novel De Novo Gain-of-Function RAC2 Mutation

A Novel RUNX2 Mutation in Cleidocranial Dysplasia Patients.

A Novel RFXANK Mutation in a Chinese Child with MHC II Deficiency: Case Report and Literature Review

Clinical and functional spectrum of RAC2-related immunodeficiency

Heterozygous activating mutation in RAC2 causes infantile-onset combined immunodeficiency with susceptibility to viral infections

A Novel Mutation of LRSAM1 in a Chinese Family with Charcot-Marie-Tooth Disease

A Novel RAB7 Mutation in a Chinese Family with Charcot-Marie-Tooth Type 2B Disease.

Case Report: Novel Splicing Mutations in RFX5 Causing MHC Class II Deficiency

RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation

Phenotypic spectrum in a family with a novel RAC2 p.I21S dominant‐activating mutation

Case Report: Profound newborn leukopenia related to a novel RAC2 variant

Rac'n'rolling the immune system

A novel nonsense mutation and polymorphisms in the mouse hairless gene.

A Novel Missense Mutation in the FERM Domain Containing 7 (FRMD7) Gene Causing X-linked Idiopathic Congenital Nystagmus in a Chinese Family.

A Novel Homozygous RHOH Variant Associated with T Cell Dysfunction and Recurrent Opportunistic Infections

A Novel TRAF3IP2 Mutation Causing Chronic Mucocutaneous Candidiasis

A novel loss of function mutation in the PHD domain of the RAG2 gene, affecting zinc-binding affinity

A Novel CNTNAP2 Mutation Results in Abnormal Neuronal E/I Balance

Combined immunodeficiency caused by a novel homozygous NFKB1 mutation

A Novel 18-Bp In-Frame Deletion Mutation in RUNX2 Causes Cleidocranial Dysplasia